Entacapone

Quick links to important sections

Entacapone

Selected form

Treatment option: Parkinson Disease

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Entacapone

Property Description
Active ingredient Entacapone
Form Film-coated tablet (oral)
Pharmacological class Catechol-O-methyltransferase (COMT) inhibitor
Common purpose Managing "wearing-off" motor fluctuations in Parkinson's disease
Origin Synthetic, Nitrocatechol derivative

What Type of Medicine is Entacapone?

Entacapone is a synthetic, prescription-only pharmaceutical agent classified as a Catechol-O-methyltransferase (COMT) inhibitor, which belongs to the larger group of dopaminergic antiparkinsonism agents. The compound is a nitrocatechol derivative, underscoring its chemically manufactured origin. This type of drug is clinically recognized for improving the effectiveness of primary Parkinson's treatment. Unlike the dopamine precursor levodopa, Entacapone does not replace the neurotransmitter directly but acts exclusively as an adjunct medication to optimize the primary treatment, functioning as a selective and reversible inhibitor.


Composition and Physical Form

The core component of this medication is the active ingredient, Entacapone. It is formulated for oral administration and is generally supplied as a film-coated tablet. A differentiating feature is its dual availability: Entacapone is offered both as a single-entity product and as a component within a fixed-dose combination product, which integrates the active ingredient with levodopa and carbidopa. This combination status simplifies administration for patients who require the triple therapeutic approach.


General Purpose: Sustaining Levodopa's Effect

The primary general purpose of Entacapone is to address the end-of-dose motor fluctuations, commonly known as the "wearing-off" effect, experienced by adult patients with Parkinson's disease. By inhibiting the COMT enzyme in the peripheral tissues, Entacapone protects levodopa from premature breakdown in the bloodstream. This protective mechanism ensures a more consistent and sustained concentration of levodopa is available, thereby helping maintain a more stable period of motor control throughout the day.

Regulatory References

  1. U.S. National Library of Medicine (NIH)
  2. European Medicines Agency (EMA)

What side effects are possible with Entacapone?

Possible Side Effects and Safety Information

The safety profile of Entacapone is officially documented according to categories of frequency and affected organ systems. The most common adverse effects are directly related to the drug's function of potentiating levodopa.

Frequency-Classified Adverse Reactions

Adverse reactions are classified in regulatory documents based on the likelihood of occurrence:

  • Very Common (ge 10%): Dyskinesia (involuntary movements), Diarrhea, and harmless urine discoloration (chromaturia).
  • Common (ge 1% to < 10%): Nausea, abdominal pain, vomiting, dry mouth, and effects on the Nervous System such as dizziness, somnolence (sleepiness), insomnia, hallucinations, and confusion. Orthostatic hypotension (low blood pressure upon standing) is also commonly reported.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list rare but clinically significant safety concerns. Serious adverse reactions include Neuroleptic Malignant Syndrome (NMS), which is associated with rapid dose reduction or withdrawal of dopaminergic agents, and Rhabdomyolysis. Rare reports of colitis and gastrointestinal haemorrhage are also documented.

Safety constraints for special populations are explicitly defined. Entacapone is officially contraindicated in patients with severe hepatic impairment due to the risk of hepatic injury. Use with non-selective Monoamine Oxidase (MAO) inhibitors is also contraindicated. Furthermore, an association with Impulse Control Disorders (e.g., pathological gambling) is documented when used with levodopa.

Time-related safety patterns indicate that dopaminergic effects, such as increased dyskinesia, are most frequently observed and may necessitate adjustment of the co-administered levodopa dose in the initial weeks after starting treatment.

Overdose and Emergency Response

Entacapone Overdose and When to Seek Help

The official regulatory profile for Entacapone overdose is defined by the necessary response to an excessive increase in dopaminergic activity resulting from the drug’s use. Overdose is expected to result in manifestations of exaggerated dopaminergic stimulation.


Documented Clinical Manifestations and Severe Outcomes

The symptoms of overdose are primarily an extension of the known effects, including dyskinesia and hyperkinesia (uncontrolled, increased involuntary movements). Gastrointestinal symptoms such as nausea and vomiting may also occur. Regulatory documents note that potential severe outcomes include Neuroleptic Malignant Syndrome (NMS)-like symptoms and, rarely, rhabdomyolysis. A benign finding often observed is the reddish-brown discoloration of urine.


Emergency Action Required

In the event of a suspected Entacapone overdose or ingestion of an excessive amount, immediate medical attention must be sought. Official guidelines state that emergency services or a Poison Control center should be contacted immediately. Hospital monitoring and general supportive care are required due to the potential for severe complications.


Management and Specific Considerations

Management of Entacapone overdose is symptomatic and supportive, as no specific antidote is known. Procedures such as gastric lavage and administration of activated charcoal may be considered to limit systemic absorption. A specific consideration is that patients with hepatic impairment show approximately two-fold higher drug exposure, which is relevant to the management of an overdose situation.

Therapeutic Uses of Entacapone

Entacapone is a medicine commonly used to help with symptoms related to physical discomfort and symptoms that interfere with daily functioning in patients managing Parkinson's disease. The therapeutic use involves combination with other treatments. It is applied across domains where additional symptomatic support is needed for people experiencing end-of-dose motor fluctuations—a condition characterized by periods of heightened symptoms, specifically easing stiffness, slowness of movement, and periods of difficult movement.


Quick Fact: Support for Symptom Fluctuations


This medicine may assist with helping patients cope more steadily with symptom fluctuations, particularly during phases when symptoms become more noticeable. The clinical role is relevant when supportive symptom management is appropriate, as it may be part of symptomatic management applied across conditions characterized by periods of heightened symptoms. Entacapone supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load, providing supportive relief when symptoms interfere with routine activities. It supports general well-being during symptomatic phases.

Regulatory References

  1. European Medicines Agency overview of Comtan

Eligibility and Restrictions for Use

The eligibility for using Entacapone is strictly defined by regulatory documents, which establish the permitted age groups, mandatory co-therapy, and absolute contraindications. Entacapone is approved only for use in adult patients (18 years and older) and must be administered as an adjunct to levodopa/carbidopa or levodopa/benserazide therapy.

Absolute Contraindications

Entacapone is contraindicated (must not be used) in patients with:

  • Known hypersensitivity to the active substance or its excipients.
  • Hepatic impairment (liver disease).
  • Phaeochromocytoma (a type of adrenal gland tumor).
  • Concomitant use with nonselective MAO inhibitors.
  • A previous history of Neuroleptic Malignant Syndrome (NMS) or non-traumatic rhabdomyolysis.

Age and Physiological Restrictions

Population Regulatory Status
Pediatric (<18 years) Not recommended; safety and efficacy have not been established.
Older Adults (Geriatric) No dose adjustment is required based on age alone.
Pregnancy/Breastfeeding Should not be used (due to lack of human data).

Use requires caution in patients with biliary obstruction, major psychotic disorder, and for those on dialysis therapy, where a longer dosing interval may be considered.

What should I know about interactions with other medicines?

The official regulatory profile for Entacapone is defined by specific interaction-related restrictions and pharmacokinetic changes with co-administered substances.

Contraindications and Administration Rules

Co-administration is formally contraindicated with non-selective Monoamine Oxidase (MAO) Inhibitors due to the potential for serious hypertensive reactions.

To prevent the formation of chelates in the gastrointestinal tract, the regulatory labels mandate a timing rule for oral iron preparations. Entacapone must be taken at least two to three hours apart from oral iron salts to avoid reducing the effectiveness of the iron.

Exposure Modification and Potentiation

Entacapone significantly alters the pharmacokinetics of certain co-administered drugs. It increases the plasma Area Under the Curve (AUC) of levodopa by approximately 35-40%, which is a documented clinical goal. A similar pharmacokinetic interaction occurs with the anticoagulant R-Warfarin, for which Entacapone increases the AUC by an average of 18%, leading to an official average increase in the International Normalized Ratio (INR).

Pharmacodynamic potentiation is a risk when Entacapone is combined with other catechol-structured compounds, such as epinephrine and dopamine. Furthermore, official prescribing information notes that patients with hepatic impairment show approximately two-fold higher Entacapone exposure (AUC and Cmax), which results in a contraindication in cases of severe impairment.

Mechanism of Action

Entacapone's mechanism is defined by peripheral enzyme inhibition, with no direct central nervous system receptor action. Its role is to preserve the bioavailability of levodopa (L-DOPA), the precursor molecule required for dopamine synthesis.

Peripheral Enzyme Inhibition and Substrate Protection

Entacapone's core mechanism is the selective and reversible inhibition of the enzyme Catechol-O-methyltransferase (COMT), primarily located in peripheral tissues outside the brain. By blocking this enzyme, the drug prevents the enzymatic breakdown of levodopa into the inactive substance, 3-O-methyldopa (3-OMD).

Synergistic Delivery for Central Stabilization

Inhibition of peripheral levodopa metabolism results in a prolongation of the half-life and elevated systemic concentration of the precursor. This mechanism works synergistically with carbidopa (which blocks a different degradation pathway, AADC), contributing to increased L-DOPA availability for transport across the blood-brain barrier. The resulting physiological effect is a less variable transfer of L-DOPA to the central nervous system, which facilitates sustained precursor availability for dopamine synthesis.

Dosage and Administration Information

How to Use Entacapone

Entacapone is an adjunctive medicine whose administration is strictly coupled with a levodopa combination product (such as levodopa/carbidopa or levodopa/benserazide). It is delivered via the oral route as a film-coated tablet, typically in a 200 mg strength.

Official Dosing and Frequency

Administration is dose-dependent: one 200 mg tablet of Entacapone must be taken with each dose of the levodopa combination. It must not be administered as a standalone therapy. The maximum recommended daily dose varies by region, with the US label specifying 1,600 mg and the EU label specifying 2,000 mg. The medication is generally intended for long-term use as part of a chronic management plan.

Administration Conditions and Adjustments

Entacapone may be taken with or without food. A key procedural constraint involves co-administration with iron products; a separation of at least two to three hours is required between Entacapone and any iron preparation to prevent impaired absorption.

Upon initiation of Entacapone, the dose of the accompanying levodopa preparation may need to be reduced to manage levodopa-related effects, a common step in the official titration process. No specific dose adjustments are typically required for older adults or in cases of renal impairment. The safety and effectiveness of Entacapone have not been established in patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Entacapone

1. Evidence Overview for Motor Fluctuations and "Wearing-Off"

Entacapone was evaluated in research exploring its role as an addition to levodopa therapy for adults with Parkinson's disease who experience motor fluctuations, often described as the "wearing-off" effect. This is a condition characterized by fluctuating or episodic manifestations where the effectiveness of the primary levodopa treatment starts to decrease before the next dose is taken. The majority of the available research involves this patient population.

The core research examined short-term changes in daily motor control. This evidence is derived from Randomized Controlled Trials (RCTs). These trials observed groups that were randomly assigned to receive either Entacapone or a placebo, both added to their existing levodopa therapy, over defined time intervals, usually lasting up to six months. These studies monitored outcomes reflecting daily functioning or activity level.

1.1. How Entacapone Trials Measured Changes in Daily Motor Status

Trials reported measurements of the total time participants were in the "ON state" (defined as a period of relatively stable movement) and the total time in the "OFF state" (defined as a period of heightened symptoms). Findings describe patterns observed in the studies regarding changes in these states compared to the control group. Researchers also evaluated outcomes using formal rating scales, such as the Unified Parkinson's Disease Rating Scale (UPDRS), to monitor movement and daily activity levels.

3. Duration of Follow-Up: Long-Term Studies and Maintenance

Most foundational evidence comes from short-term clinical trials. To gather information about use over longer durations, researchers employed open-label extension studies and observational cohort studies, tracking outcomes up to three years. However, long-term effects are not fully established. Follow-up durations were limited for many participants in these extended studies, and high rates of patient discontinuation were frequently reported. This means that data are still emerging regarding how treatment patterns evolve over many years.

5. What is Still Uncertain About Entacapone Research

A key limitation is that the primary RCTs focused on short-term symptom changes. Furthermore, comparative evidence is lacking for certain scenarios, with limited head-to-head studies comparing Entacapone to the newer COMT inhibitors or other advanced therapies that may be used for similar purposes.

Key Studies & References Entacapone (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Entacapone (FAQ)


Q: Is Entacapone a brand name or a generic drug?

Entacapone is the generic name of the medicine. It is available both under its original brand name (such as Comtan) and as several generic versions, depending on the manufacturer and market.


Q: How quickly should Entacapone start working?

Entacapone's primary effect on levodopa starts immediately upon administration. Because the medication works to enhance the effects of levodopa, official prescribing information notes that adjustments to the levodopa dose are often required within the first few days to weeks of starting Entacapone, suggesting when the change in therapeutic effect is commonly observed.


Q: What happens if I stop taking Entacapone?

Regulatory warnings are associated with the abrupt discontinuation of this medication. Suddenly stopping Entacapone or similar dopaminergic agents has been associated with serious health concerns, including a condition called Neuroleptic Malignant Syndrome (NMS). Any decision regarding treatment cessation should be made by a healthcare provider.


Q: Can Entacapone change the color of urine or sweat?

Yes, Entacapone is commonly associated with harmless urine discoloration. Regulatory information states that urine often turns a reddish-brown or black color. Furthermore, post-marketing reports indicate that other body fluids, such as sweat and saliva, may also become discolored.


Q: Are there any long-term side effects associated with Entacapone use?

Entacapone is intended for long-term use as part of chronic Parkinson's management. Official safety information advises that certain risks require monitoring during extended treatment, including the potential association with melanoma and, in some studies, an increased risk of prostate cancer.


Q: Does Entacapone interact with alcohol?

Yes, official information indicates that consumption of alcohol may increase nervous system side effects, such as dizziness, drowsiness, and difficulty concentrating. Therefore, the use of alcohol is advised to be avoided or limited while taking this medication.


Q: Are there any supplements that should not be taken with Entacapone?

Certain types of supplements are advised to be avoided. Entacapone is formally contraindicated (should not be used) with non-selective Monoamine Oxidase (MAO) inhibitors. Additionally, the regulatory mandate requires separation from any supplement containing oral iron salts by at least two to three hours to prevent impaired absorption.


Q: Is there any research on Entacapone for restless legs syndrome?

Entacapone is only approved for use in adult patients with Parkinson's disease to manage motor fluctuations. There are no regulatory approvals for using this medication to treat restless legs syndrome (RLS). Its prescribed role remains strictly to enhance the effects of levodopa for motor fluctuations in Parkinson's.


Q: What happens if I miss a dose of Entacapone?

If a dose is missed, regulatory patient information provides non-directive guidance. If the lapse is remembered soon after, the missed dose may be taken. However, if it is almost time for the next scheduled dose, the instruction is to skip the missed dose and resume the regular schedule, avoiding a double dose.


Q: How is Entacapone different from other Parkinson's medicines like dopamine agonists?

Entacapone belongs to a class of medications called COMT inhibitors. Its purpose is to protect levodopa from being broken down in the bloodstream, making more of it available to the brain. In contrast, medicines known as dopamine agonists work by directly activating and mimicking the effects of dopamine in the brain.


Q: Do I need to change my diet while taking Entacapone?

No major dietary changes are generally required, and the medication can be taken with or without food. However, official information mandates that the Entacapone dose must be separated from any oral iron supplements or preparations by at least two to three hours to avoid impaired absorption.


Q: What foods or beverages should I avoid when using Entacapone?

Official information indicates that consumption of alcohol may increase nervous system side effects. Additionally, the regulatory mandate requires separation from oral iron supplements by two to three hours to prevent absorption issues.


Q: What is the general success rate mentioned in studies for Entacapone?

Clinical research has focused on improvements in motor control time. Studies observed that when Entacapone was added to levodopa therapy, patients experienced a statistically significant increase in the total amount of 'ON' time (when movement is relatively stable). This finding indicates its effect on managing motor fluctuations compared to a control group.


Q: How often do I need to see my doctor while on Entacapone?

Official documents emphasize the need for ongoing monitoring. Regulatory safety information recommends that patients and healthcare providers perform periodic skin examinations due to an observed risk of melanoma. They also stress the importance of adhering to routine examinations for conditions like prostate cancer during long-term treatment.


Q: Can Entacapone be taken with a multivitamin?

It is advised to check if a multivitamin contains iron. Since many multivitamins include oral iron, regulatory information advises separating the administration of Entacapone from the multivitamin by at least two to three hours. This time separation helps prevent impaired absorption of the iron.


Q: Is Entacapone the only COMT inhibitor available?

No, Entacapone is not the only medication in the COMT inhibitor class. Other drugs, such as tolcapone and opicapone, are also approved for similar use as an addition to levodopa therapy for Parkinson's disease.


Q: Is Entacapone approved for use in all countries?

Entacapone is approved for use and regulated by major international authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its availability and specific labeling in other countries depend on that nation's independent regulatory approval process.


Q: Do studies suggest Entacapone helps improve overall quality of life?

Clinical research primarily measures improvements in motor control. Studies focus on objective metrics like increased 'ON' time and decreased 'OFF' time, which are recognized factors contributing to better daily functioning and a patient's overall quality of life.


Q: Does Entacapone cause weight gain or loss?

Weight changes are not listed as a common side effect of the drug itself. However, diarrhea is a very common reported side effect of Entacapone, and official documents note that severe or persistent diarrhea may lead to dehydration and weight loss, which should be monitored.


Q: What should I do if a specific side effect doesn't go away?

Immediate medical attention is advised for serious side effects. Official regulatory guidelines specify symptoms that warrant immediate contact with a physician, such as high fever, hallucinations, or severe muscle stiffness. For common or bothersome side effects that persist, a prescribing doctor or pharmacist should be informed.


Q: Does Entacapone have a risk of addiction or dependence?

The use of Entacapone with levodopa has been associated with Impulse Control Disorders (ICDs). These disorders involve intense urges, such as pathological gambling, hypersexuality, and compulsive shopping. This is a behavioral side effect noted in the official safety information.


Q: Is Entacapone a cure for Parkinson's disease?

No, Entacapone is not a cure for Parkinson's disease. According to official information, the drug is intended to help control the symptoms of the disease and manage motor fluctuations by enhancing the effect of levodopa.


Q: What research is currently being done on Entacapone?

Research into Entacapone is ongoing. Publicly accessible regulatory trial databases, such as ClinicalTrials.gov, list current studies that continue to evaluate the drug, including its long-term safety profile and potential for use in new patient populations or conditions.


Q: Can Entacapone be split or crushed?

Official instructions state that Entacapone tablets are film-coated and are not intended to be split or crushed. The product labeling advises that tablets should be administered whole.


Q: Are there any mandatory tests required before starting Entacapone?

The medication is contraindicated for patients with severe liver impairment. Because of this safety constraint, a physician will typically assess a patient’s liver function to ensure eligibility before starting treatment, even though specific mandatory tests are not explicitly detailed in the labeling.


Q: Does Entacapone help tremors?

The primary approved use of Entacapone is for managing motor fluctuations. While tremor is a common symptom of Parkinson's disease, regulatory documents indicate that tremor is sometimes reported as a common side effect (or worsening of an existing symptom) during treatment.

How should Entacapone be stored and disposed of?

How to Store and Dispose of Entacapone?

Entacapone tablets require specific conditions to maintain their stability, as defined by regulatory documents.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F).
Protection Keep away from heat, moisture, and direct light. Do not freeze.
Container Store in a closed container.
Child Safety Keep out of the sight and reach of children.

Disposal

Discard unused or expired Entacapone according to local requirements. The medicine must not be disposed of via wastewater or household waste. Patients should consult a healthcare professional for specific instructions on discarding medication that is no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Entacapone found in:

A-Z Index: